Nurix Therapeutics' GAAP loss for 6 months of fiscal year 2022 was $87.934 million, up 73.6% from $50.657 million in the prior year. Revenue increased 74% to $21.053 million compared to $12.102 million a year earlier.
Nurix Therapeutics' GAAP loss for 6 months of fiscal year 2022 was $87.934 million, up 73.6% from $50.657 million in the prior year. Revenue increased 74% to $21.053 million compared to $12.102 million a year earlier. 
ir.nurixtx.com
English (US) 